Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment
Locally advanced or metastatic urothelial bladder cancer (a/m UBC) is currently treated using platinum-based combination chemotherapy. Immune checkpoint inhibitors (ICIs) are the preferred second-line treatment options for cisplatin-eligible a/m UBC patients and as first-line options in cisplatin-in...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-09-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/22/17/9526 |
| _version_ | 1797521330986287104 |
|---|---|
| author | Hye Won Lee Ho Kyung Seo |
| author_facet | Hye Won Lee Ho Kyung Seo |
| author_sort | Hye Won Lee |
| collection | DOAJ |
| description | Locally advanced or metastatic urothelial bladder cancer (a/m UBC) is currently treated using platinum-based combination chemotherapy. Immune checkpoint inhibitors (ICIs) are the preferred second-line treatment options for cisplatin-eligible a/m UBC patients and as first-line options in cisplatin-ineligible settings. However, the response rates for ICI monotherapy are modest (~20%), which necessitates the exploration of alternative strategies. Dysregulated activation of fibroblast growth factor receptor (FGFR) signaling enhances tumor proliferation, survival, invasion, angiogenesis, and immune evasion. The recent U.S. Food and Drug Administration approval of erdafitinib and the emergence of other potent and selective FGFR inhibitors (FGFRis) have shifted the treatment paradigm for patients with a/m UBC harboring actionable FGFR2 or FGFR3 genomic alterations, who often have a minimal-to-modest response to ICIs. FGFRi–ICI combinations are therefore worth exploring, and their preliminary response rates and safety profiles are promising. In the present review, we summarize the impact of altered FGFR signaling on a/m UBC tumor evolution, the clinical development of FGFRis, the rationale for FGFRi–ICI combinations, current trials, and prospective research directions. |
| first_indexed | 2024-03-10T08:10:02Z |
| format | Article |
| id | doaj.art-b8dee169b0864106bc2d27904ee205b6 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-10T08:10:02Z |
| publishDate | 2021-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-b8dee169b0864106bc2d27904ee205b62023-11-22T10:44:53ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-09-012217952610.3390/ijms22179526Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune MicroenvironmentHye Won Lee0Ho Kyung Seo1Department of Urology, Center for Urologic Cancer, National Cancer Center, Goyang 10408, KoreaDepartment of Urology, Center for Urologic Cancer, National Cancer Center, Goyang 10408, KoreaLocally advanced or metastatic urothelial bladder cancer (a/m UBC) is currently treated using platinum-based combination chemotherapy. Immune checkpoint inhibitors (ICIs) are the preferred second-line treatment options for cisplatin-eligible a/m UBC patients and as first-line options in cisplatin-ineligible settings. However, the response rates for ICI monotherapy are modest (~20%), which necessitates the exploration of alternative strategies. Dysregulated activation of fibroblast growth factor receptor (FGFR) signaling enhances tumor proliferation, survival, invasion, angiogenesis, and immune evasion. The recent U.S. Food and Drug Administration approval of erdafitinib and the emergence of other potent and selective FGFR inhibitors (FGFRis) have shifted the treatment paradigm for patients with a/m UBC harboring actionable FGFR2 or FGFR3 genomic alterations, who often have a minimal-to-modest response to ICIs. FGFRi–ICI combinations are therefore worth exploring, and their preliminary response rates and safety profiles are promising. In the present review, we summarize the impact of altered FGFR signaling on a/m UBC tumor evolution, the clinical development of FGFRis, the rationale for FGFRi–ICI combinations, current trials, and prospective research directions.https://www.mdpi.com/1422-0067/22/17/9526urothelial bladder carcinomaprecision medicinefibroblast growth factor receptorfibroblast growth factor inhibitortumor microenvironmenttreatment resistance |
| spellingShingle | Hye Won Lee Ho Kyung Seo Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment International Journal of Molecular Sciences urothelial bladder carcinoma precision medicine fibroblast growth factor receptor fibroblast growth factor inhibitor tumor microenvironment treatment resistance |
| title | Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment |
| title_full | Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment |
| title_fullStr | Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment |
| title_full_unstemmed | Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment |
| title_short | Fibroblast Growth Factor Inhibitors for Treating Locally Advanced/Metastatic Bladder Urothelial Carcinomas via Dual Targeting of Tumor-Specific Oncogenic Signaling and the Tumor Immune Microenvironment |
| title_sort | fibroblast growth factor inhibitors for treating locally advanced metastatic bladder urothelial carcinomas via dual targeting of tumor specific oncogenic signaling and the tumor immune microenvironment |
| topic | urothelial bladder carcinoma precision medicine fibroblast growth factor receptor fibroblast growth factor inhibitor tumor microenvironment treatment resistance |
| url | https://www.mdpi.com/1422-0067/22/17/9526 |
| work_keys_str_mv | AT hyewonlee fibroblastgrowthfactorinhibitorsfortreatinglocallyadvancedmetastaticbladderurothelialcarcinomasviadualtargetingoftumorspecificoncogenicsignalingandthetumorimmunemicroenvironment AT hokyungseo fibroblastgrowthfactorinhibitorsfortreatinglocallyadvancedmetastaticbladderurothelialcarcinomasviadualtargetingoftumorspecificoncogenicsignalingandthetumorimmunemicroenvironment |